| Date | Price Target | Rating | Analyst |
|---|
LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Compensation Committee of the Company's Board of Directors approved inducement grants of stock options to purchase a total of 30,575 shares of common stock and 8,750 restricted stock units (“RSUs”) to be distributed among six new employees with a grant date of Dec. 1, 2020 (the “Inducement Grants”). The stock options approved under the Inducement Grants were issued pursuant to Dicerna’s 2016 Inducement Plan and have an exercise price per share equal to $24.76,
SC 13G/A - ALEXION PHARMACEUTICALS, INC. (0000899866) (Subject)
SC 13G/A - ALEXION PHARMACEUTICALS, INC. (0000899866) (Subject)
SC 13G/A - ALEXION PHARMACEUTICALS, INC. (0000899866) (Subject)
SC 13G/A - ALEXION PHARMACEUTICALS, INC. (0000899866) (Subject)
4 - ALEXION PHARMACEUTICALS, INC. (0000899866) (Issuer)
4 - ALEXION PHARMACEUTICALS, INC. (0000899866) (Issuer)
4 - ALEXION PHARMACEUTICALS, INC. (0000899866) (Issuer)
4 - ALEXION PHARMACEUTICALS, INC. (0000899866) (Issuer)
4 - ALEXION PHARMACEUTICALS, INC. (0000899866) (Issuer)
4 - ALEXION PHARMACEUTICALS, INC. (0000899866) (Issuer)
4 - ALEXION PHARMACEUTICALS, INC. (0000899866) (Issuer)
4 - ALEXION PHARMACEUTICALS, INC. (0000899866) (Issuer)
4 - ALEXION PHARMACEUTICALS, INC. (0000899866) (Issuer)
4 - ALEXION PHARMACEUTICALS, INC. (0000899866) (Issuer)
15-12G - ALEXION PHARMACEUTICALS, INC. (0000899866) (Filer)
EFFECT - ALEXION PHARMACEUTICALS, INC. (0000899866) (Filer)
EFFECT - ALEXION PHARMACEUTICALS, INC. (0000899866) (Filer)
EFFECT - ALEXION PHARMACEUTICALS, INC. (0000899866) (Filer)
EFFECT - ALEXION PHARMACEUTICALS, INC. (0000899866) (Filer)
EFFECT - ALEXION PHARMACEUTICALS, INC. (0000899866) (Filer)
EFFECT - ALEXION PHARMACEUTICALS, INC. (0000899866) (Filer)
EFFECT - ALEXION PHARMACEUTICALS, INC. (0000899866) (Filer)
EFFECT - ALEXION PHARMACEUTICALS, INC. (0000899866) (Filer)
EFFECT - ALEXION PHARMACEUTICALS, INC. (0000899866) (Filer)
Oppenheimer upgraded Alexion Pharma from Perform to Outperform and set a new price target of $205.00
Credit Suisse resumed coverage of Alexion Pharma with a rating of Neutral and set a new price target of $190.00
SVB Leerink downgraded Alexion Pharma from Outperform to Mkt Perform
SVB Leerink downgraded Alexion Pharmaceuticals from Outperform to Market Perform and set a new price target of $156.00 from $196.00 previously
SVB Leerink reiterated coverage of Alexion Pharmaceuticals with a rating of Outperform and set a new price target of $196.00 from $200.00 previously
Piper Sandler downgraded Alexion Pharmaceuticals from Overweight to Neutral
NEW YORK, July 15, 2021 /PRNewswire/ -- Moderna Inc. (NASD:MRNA) will replace Alexion Pharmaceuticals Inc. (NASD:ALXN) in the S&P 500 effective prior to the opening of trading on Wednesday, July 21. AstraZeneca Plc (LSE:AZN; NASD:AZN) is acquiring Alexion Pharmaceuticals in a deal expected to be completed soon pending final closing conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name Action Company Name Ticker GICS Sector July 21, 2021 S&P 500 Addition Moderna MRNA Health Care S&P 500 Deletion Alexion Pharmaceuticals ALXN Health Care For more information about S&P Dow Jones Indices, please
– Study met primary endpoint of change from baseline in the Myasthenia Gravis-Activities of Daily Living Profile (MG-ADL) total score at Week 26 – – ULTOMIRIS demonstrated compelling efficacy as early as Week 1, sustained for 52 weeks – Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced positive topline results from a Phase 3 study evaluating the safety and efficacy of ULTOMIRIS® (ravulizumab-cwvz) in adults with generalized myasthenia gravis (gMG). The study met, with high statistical significance, its primary endpoint of change from baseline in the Myasthenia Gravis-Activities of Daily Living Profile (MG-ADL) total score, a patient-reported assessment, at Week 26, and for the s
NEW YORK, July 14, 2021 (GLOBE NEWSWIRE) -- Nasdaq (NASDAQ:NDAQ) today announced that Honeywell International Inc. (NASDAQ:HON), will become a component of the NASDAQ-100 Index® (NASDAQ:NDX), the NASDAQ-100 Equal Weighted Index (NASDAQ:NDXE) and the NASDAQ-100 Ex-Technology Index (NASDAQ:NDXX) prior to market open on Wednesday, July 21, 2021. Honeywell International Inc. will replace Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) in the NASDAQ-100 Index®, the NASDAQ-100 Equal Weighted Index and the NASDAQ-100 Ex-Technology Index. For more information about the company, go to https://www.honeywell.com/ . About Nasdaq Nasdaq (NASDAQ:NDAQ) is a global technology company serving the capital ma
BORDENTOWN, N.J. & BOSTON--(BUSINESS WIRE)--Caelum Biosciences and Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced new Phase 2 safety and tolerability data for CAEL-101, a potentially first-in-class amyloid fibril targeted therapy, in combination with standard-of-care (SoC) therapy in patients with AL amyloidosis. The data, presented in two e-posters at the European Hematology Association (EHA) Congress 2021, strengthen the safety and tolerability profile of CAEL-101, further support the dose selection for the ongoing Phase 3 study, and suggest possible cardiac and renal response. An e-poster featuring the first data from a new arm of the study demonstrated that CAEL-101
BOSTON--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced the U.S. Food and Drug Administration (FDA) has approved the expanded use of ULTOMIRIS® (ravulizumab-cwvz) to include children (one month of age and older) and adolescents with paroxysmal nocturnal hemoglobinuria (PNH). ULTOMIRIS, a long-acting C5 inhibitor that offers immediate, complete and sustained complement inhibition, is now the first and only FDA-approved medicine for children and adolescents with PNH. “It can take months, and sometimes years, to receive a correct diagnosis for PNH — a chronic, progressive and potentially life-threatening rare disease – which can be an overwhelming experien
- Accepted abstracts include new Phase 2 safety and tolerability data for CAEL-101 in AL amyloidosis - - Phase 3 studies of CAEL-101 in AL amyloidosis are underway - Caelum Biosciences and Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that two abstracts on CAEL-101, a potentially first-in-class amyloid fibril targeted therapy, have been accepted for e-poster presentation at the European Hematology Association (EHA) Congress 2021, taking place virtually from June 9 to 17, 2021. Both presentations will include new data from the Phase 2 open-label dose escalation study evaluating the safety and tolerability of CAEL-101 in combination with standard-of-care (SoC) therapy in AL amy
– Long-term data evaluate the effectiveness of ULTOMIRIS® (ravulizumab-cwvz) in reducing the risk of thrombosis in PNH, the primary cause of organ damage and premature death in untreated patients – – Accepted abstracts include new interim Phase 3 data studying the safety and efficacy of ULTOMIRIS in pediatric patients – Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that five abstracts have been accepted for presentation at the 26th annual European Hematology Association (EHA) 2021 virtual Congress, taking place from June 9 through June 17, 2021. During the meeting, data will be presented further supporting the long-term safety of ULTOMIRIS® (ravulizumab-cwvz) over two years,
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that its shareholders have voted to adopt and approve the previously announced agreement to be acquired by AstraZeneca at a special meeting of shareholders held today. Ludwig Hantson, Ph.D., Chief Executive Officer, Alexion, said: "We're very pleased with today's affirmative shareholder vote, which brings us one step closer to completing a transaction that will accelerate the combined company's ability to develop and provide access to life-changing medicines for patients with rare and devastating diseases around the world." Subject to receipt of additional regulatory clearances, the acquisition is expected to close in the third q
1Q21 total revenues of $1,636.5 million, a 13% increase over 1Q20 1Q21 GAAP diluted EPS of $2.86; non-GAAP diluted EPS of $3.52 Completed enrollment in Phase 3 studies of ULTOMIRIS® (ravulizumab) in NMOSD and ALS Filed for regulatory approval of ONDEXXYA® [coagulation factor Xa (recombinant), inactivated-zhzo] in Japan Secured UK reimbursement for ULTOMIRIS in PNH and ONDEXXYA for GI bleeds Received U.S. Federal Trade Commission clearance for proposed acquisition by AstraZeneca; transaction expected to close in 3Q21 Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced financial results for the first quarter of 2021. Total revenues in the first quarter were $1,636.5
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that the Company will report its financial results for the first quarter ended March 31, 2021 before the US financial markets open on April 30, 2021, rather than on May 3, 2021 as previously announced. Given the previously announced agreement to be acquired by AstraZeneca, Alexion will not be hosting a conference call. Earnings materials will be made available publicly on the Investor Relations page of our website at http://ir.alexion.com. Questions may be directed to the Investor Relations team via e-mail at [email protected] or the contact information below. AstraZeneca and Alexion Combination On December 12, 2020,